{"id":18585,"date":"2025-12-02T08:20:00","date_gmt":"2025-12-02T13:20:00","guid":{"rendered":"https:\/\/www.purdue.edu\/newsroom\/?p=18585"},"modified":"2025-12-04T10:33:15","modified_gmt":"2025-12-04T15:33:15","slug":"new-chemistry-helps-make-the-medicines-people-need","status":"publish","type":"post","link":"https:\/\/www.purdue.edu\/newsroom\/2025\/Q4\/new-chemistry-helps-make-the-medicines-people-need","title":{"rendered":"New chemistry helps make the medicines people need"},"content":{"rendered":"\n

WEST LAFAYETTE, Ind. \u2014 Imagine that a new lifesaving medication is invented, but its unusual structure makes it difficult to manufacture. The drug might turn out to be prohibitively expensive or supply might be scarce, and so it might not be made at all. At Purdue University, chemist Christopher Uyeda<\/a> is working to head off this problem. In at least one instance, he already has.<\/p>\n\n\n\n

Uyeda, the Herbert C. Brown Chair in Chemistry in the College of Science<\/a>, is an expert in catalysts, substances that accelerate chemical reactions. He aims to use substances that are safe and readily available in his development of chemical reactions for manufacturing pharmaceuticals, materials for energy applications and agrochemicals.<\/p>\n\n\n\n

\u201cIn my lab, we think about what structures are very important in organic chemistry but are currently very difficult to make, and then how can we design a catalyst to accomplish that,\u201d Uyeda said.<\/p>\n\n\n\n

His work builds on a long-standing strength in organic chemistry at Purdue, including Nobel Prize-winning work<\/a> on designing new reactions. Uyeda\u2019s work is part of Purdue\u2019s One Health initiative<\/a>, which brings together research on human, animal and plant health. His research supports the initiative\u2019s focus on advanced chemistry, where Purdue faculty study complex chemical systems and develop new techniques and applications.<\/p>\n\n\n\n

Uyeda\u2019s lab specializes in two areas of research: designing small synthetic catalysts that can tackle tough reactions without compromising on precision, and designing new reactions to manufacture cyclopropanes \u2014 a triangle of three carbon atoms, often found in drug compounds.<\/p>\n\n\n\n

A reaction he designed<\/a> is now used as part of Pfizer\u2019s process for manufacturing Paxlovid<\/a>, the first-in-line treatment for COVID-19 initially authorized for use by the Food and Drug Administration in December 2021. The molecule requires a cyclopropane that is difficult to synthesize and not easily obtained from natural sources.<\/p>\n\n\n\n

Fortunately, Uyeda\u2019s lab developed a reaction, years before COVID, that uses a cobalt catalyst to make the exact type of cyclopropane needed from safe and commonly available materials, facilitating a cost-effective manufacturing process.<\/p>\n\n\n\n

Uyeda produces cyclopropanes by combining one point in the carbon triangle \u2014 a single-carbon component called a carbene \u2014 with an existing two-carbon component. To do so, he must first generate the carbene, which is a highly reactive molecule. The carbene used in Paxlovid, for example, sprouts two methyl groups from its carbon, which also bonds to the two-carbon component. Chemists typically rely on high-energy reagents to generate carbenes, a process that poses safety risks. Uyeda is developing reactions that use new catalysts to generate carbenes from stable molecules.<\/p>\n\n\n\n

One of his research goals is to develop what he calls a universal set of coupling reactions that will allow him to attach any type of carbene to a molecule as needed.<\/p>\n\n\n\n

\u201cOur approach allows industries to think about this type of chemistry without the safety concerns associated with high-energy reagents,\u201d Uyeda said. Additionally, the new catalysts he uses take advantage of common metals, like cobalt and nickel, which are abundant, readily accessible and inexpensive.<\/p>\n\n\n\n

\"A
A reaction that catalysis expert Christopher Uyeda designed is now part of the manufacturing process for Pfizer\u2019s first-in-line COVID-19 treatment Paxlovid. (Purdue University photo\/Kelsey Lefever)<\/figcaption><\/figure>\n\n\n\n

A really good catalyst drives a lot of the reaction that\u2019s desired and nothing else, traits known as activity and selectivity. Uyeda works with homogeneous catalysts: small, synthetic molecules prized for their selectivity. These types of catalysts can lack raw muscle when contrasted with another type, heterogeneous catalysts \u2014 often used in industrial processes \u2014 that rely on large metal particles to drive a reaction. Like sticking molecules to a piece of packing tape, the broad surface area of heterogeneous catalysts catches the molecule at multiple points, stabilizing it during tough reactions. The downside is that the broad surface area can also breed unwanted reactions. Uyeda\u2019s work<\/a> is incorporating the strength<\/a> of heterogeneous catalysts into the world of homogeneous catalysts.<\/p>\n\n\n\n

\u201cWe design systems that allow you to incorporate more than one metal into a homogeneous catalyst. That gives us much more control over the active site of the catalyst \u2014 we know exactly what reaction it\u2019s going to do. And that\u2019s something that people haven\u2019t been that successful at doing before,\u201d Uyeda said.<\/p>\n\n\n\n

Uyeda\u2019s research on carbene transfer reactions is funded by the National Institutes of Health, and his work on stronger catalysts is funded by the National Science Foundation and U.S. Department of Energy, Office of Science.<\/p>\n\n\n\n

About Purdue University<\/h2>\n\n\n\n

Purdue University is a public research university leading with excellence at scale. Ranked among top 10 public universities in the United States, Purdue discovers, disseminates and deploys knowledge with a quality and at a scale second to none. More than 106,000 students study at Purdue across multiple campuses, locations and modalities, including more than 57,000 at our main campus locations in West Lafayette and Indianapolis. Committed to affordability and accessibility, Purdue\u2019s main campus has frozen tuition 14 years in a row. See how Purdue never stops in the persistent pursuit of the next giant leap \u2014 including its integrated, comprehensive Indianapolis urban expansion; the Mitch Daniels School of Business; Purdue Computes; and the One Health initiative \u2014 at https:\/\/www.purdue.edu\/president\/strategic-initiatives<\/a>.<\/p>\n\n\n\n

Papers<\/h2>\n\n\n\n

Cobalt-catalyzed reductive dimethylcyclopropanation of 1,3-dienes<\/em>
Angewandte Chemie
DOI: https:\/\/doi.org\/10.1002\/anie.201807542<\/a><\/p>\n\n\n\n

Development of the commercial manufacturing process for nirmatrelvir in 17 months<\/em>
ACS Central Science
DOI: https:\/\/doi.org\/10.1021\/acscentsci.3c00145<\/a><\/p>\n\n\n\n

Dinickel active sites supported by redox-active ligands<\/em>
Accounts of Chemical Research
DOI: https:\/\/doi.org\/10.1021\/acs.accounts.1c00424<\/a><\/p>\n\n\n

\n
\n
\n

\n Media contact:<\/strong> Trevor Peters, peter237@purdue.edu<\/a> <\/p>\n <\/div>\n <\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WEST LAFAYETTE, Ind. \u2014 Imagine that a new lifesaving medication is invented, but its unusual structure makes it difficult to manufacture. The drug might turn out to be prohibitively expensive or supply might be scarce, and so it might not<\/p>\n","protected":false},"author":20,"featured_media":18514,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[315],"tags":[],"department":[],"source":[29],"purdue_today_topic":[],"coauthors":[127],"class_list":["post-18585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-one-health","source-purdue-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/18585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/comments?post=18585"}],"version-history":[{"count":3,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/18585\/revisions"}],"predecessor-version":[{"id":18588,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/18585\/revisions\/18588"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/media\/18514"}],"wp:attachment":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/media?parent=18585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/categories?post=18585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/tags?post=18585"},{"taxonomy":"department","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/department?post=18585"},{"taxonomy":"source","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/source?post=18585"},{"taxonomy":"purdue_today_topic","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/purdue_today_topic?post=18585"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/coauthors?post=18585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}